^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | parsaclisib (INCB50465) (PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma
Published date:
03/31/2021
Excerpt:
Innovent Biologics, Inc...a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the Center for Drug Evaluation (CDE) of China’s Nation Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for Parsaclisib (IBI376) for the treatment of patients with relapsed/refractory follicular lymphoma (FL).
